Question 1

What specific types of tumors are eligible for this study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours clinical trial (NCT07213817). Contact the study team or your healthcare provider for specific answers.

Question 2

How will the safety and effectiveness of IPN60300 be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours clinical trial (NCT07213817). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of this treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours clinical trial (NCT07213817). Contact the study team or your healthcare provider for specific answers.

Question 4

How long will I need to participate in the study, and what will the visits involve?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours clinical trial (NCT07213817). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my condition worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours clinical trial (NCT07213817). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs associated with participating in this study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours clinical trial (NCT07213817). Contact the study team or your healthcare provider for specific answers.

What this study is about